[1]桑怡菲, 李佳蕊. 微小RNA在卵巢癌中侵袭转移机制的研究进展[J]. 国际妇产科学杂志, 2018,45:76-79. [2]Zhang Z, Luo G, Yu C, et al. microRNA-493-5p inhibits proliferation and metastasis of osteosarcoma cells by targeting Kruppel like factor 5[J]. J Cell Physiol, 2019, 234:13525-13533. [3]王冠男. microRNA-493-5p对肝癌细胞增殖、凋亡及侵袭迁移作用机制的研究[D]. 安徽医科大学, 2018:1-71. [4]Wang G, Bai X, Jiang G, et al. GIT1 over-expression promotes epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma[J]. Bioengineered, 2021 12:30-43. [5]Ye X, Chen X. miR-149-5p inhibits cell proliferation and invasion through targeting GIT1 in medullary thyroid carcinoma[J]. Oncol Lett, 2019, 17:372-378. [6]冯林森, 王羽丰. 卵巢癌靶向治疗的潜在新靶点药物研究进展[J]. 国际药学研究杂志, 2017,44:909-913. [7]Deb B, Uddin A, Chakraborty S. miRNAs and ovarian cancer: an overview[J]. J Cell Physiol, 2018, 233:3846-3854. [8]Zhao L, Feng X, Song X, et al. miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4[J]. Oncol Rep, 2016, 36:1007-1015. [9]Wang G, Fang X, Han M, et al. microRNA-493-5p promotes apoptosis and suppresses proliferation and invasion in liver cancer cells by targeting VAMP2[J]. Int J Mol Med, 2018, 41:1740-1748. [10]Chang JS, Su CY, Yu WH, et al. GIT1 promotes lung cancer cell metastasis through modulating Rac1/Cdc42 activity JP3and is associated with poor prognosis[J]. Oncotarget, 2015, 6:36278-36291. [11]Zhang Z, Hu P, Xiong J, et al. Inhibiting GIT1 reduces the growth, invasion, and angiogenesis of osteosarcoma[J]. Cancer Manag Res, 2018, 10:6445-6455. [12]黄玮, 李瑞琴. MAPK/ERK 信号传导通路与肿瘤发生的相关机制研究进展[J]. 中国现代医药杂志, 2016, 18:97-100. [13]Kielbik M, Krzyzanowski D, Pawlik B, et al. Cisplatin-induced ERK1/2 activity promotes G1 to S phase progression which leads to chemoresistance of ovarian cancer cells[J]. Oncotarget, 2018, 9:19847-19860. [14]Zhao LY, Tong DD, Xue M, et al. MeCP2, a target of miR-638, facilitates gastric cancer cell proliferation through activation of the MEK1/2-ERK1/2 signaling pathway by upregulating GIT1[J]. Oncogenesis, 2017, 6:e368. doi:10.1038/oncsis.2017.60. |